Scott Gustin, DVM, MAM
Scott is a native of Gloucester, Virginia growing up on a small family farm raising registered Angus and Hereford cattle. He received his undergraduate and veterinary degrees at Virginia Tech in 1999 and 2002. He went on to receive his Masters in Avian Medicine at the University of Georgia. In 2004 he began his veterinary career at Cobb-Vantress in Siloam Springs. While at Cobb his job functions included technical service for North America and Asia, internal veterinary service, and the World Director for Quality Assurance, focusing on Salmonella eradication programs. For the past 6 years he has held the position of Director of Veterinary Services, Domestic Poultry, for Tyson Foods in Springdale, Arkansas.
Christine Adreani
Stephen Martin
As Head of Global Pharmaceutical R&D at Boehringer Ingelheim Animal Health Stephen Martin has:
- Lead functions responsible for discovering, developing, and gaining world-wide marketing authorizations for animal health medicines and health products.
- Lead the global R&D functions that support manufacturing of pharmaceutical drugs. Includes functions responsible for analytical methods, formulation, technical transfer and investigations for development and commercial products.
- Implemented and lead a team and process for collaborating with human pharma and biopharma to identify, transfer and develop human medicines for veterinary use.
- Increased pipeline value by over 50%, and number of projects and project
progression by 300%, with a neutral headcount target.
- Site leader for a GXP R&D facility (90,000 square feet)
- Member of the R&D Leadership Team and the BI Extended Leadership Team with responsibility for the execution of R&D and business strategy.
Atsushi Nagahisa
Atsushi Nagahisa, Ph.D., is President of DNA Partners LLC. Prior to forming DNA Partners, Dr. Nagahisa served on the Board of Directors of RaQualia Pharma Inc. (RaQualia), a biopharmaceutical venture he founded in 2008. He served as Representative Director, President and CEO of RaQualia from its inception through August 2012. Dr. Nagahisa raised $111 million to launch RaQualia, the first, organic spin-out in Pfizer’s history, and then in July 2011 successfully raised an additional $83 million in a public offering (IPO) on the Osaka Securities Exchange JASDAQ Growth Market. Under his leadership, RaQualia established over 300 collaborations and partnerships with institutions and corporations in 17 countries around the world. Galliprant® (grapiprant tablets) and ENTYCE® (capromorelin oral solution), approved by the U.S. Food and Drug Administration in March 2016 and May 2016, respectively, were the result of licensing deals completed between RaQualia and Aratana Therapeutics, Inc. in December 2010.